Hira Mian, Hsien Seow, Gregory R Pond, Anastasia Gayowsky, Ronan Foley, Amaris Balistky, Mohammed Ebraheem, Christopher Cipkar, Hyra Sapru, Ghulam Rehman Mohyuddin, Samer Al Hadidi, Alissa Visram
PURPOSE: This study aims to describe the treatment patterns, outcomes, health care utilization and symptom burden of triple class exposed (TCE) relapsed/refractory patents with multiple myeloma (MM) receiving a subsequent line of treatment (LOT). METHODS: This is a retrospective observational cohort study using administrative databases in Ontario, Canada. Outcomes were captured for TCE patients receiving a subsequent LOT and included: treatment regimen details, time to next treatment (TTNT), overall survival (OS), health care utilization, palliative care referral, and patient reported symptoms...
February 14, 2024: Clinical Lymphoma, Myeloma & Leukemia